Jump to content

Methamphetamine: Difference between revisions

From Pharmacopedia
[pending revision][pending revision]
Recategorize: Stimulants & Wake-Promoting Agents -> Stimulants
Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.
 
(One intermediate revision by the same user not shown)
Line 15: Line 15:
| pregnancy        = Category C (per Desoxyn label)
| pregnancy        = Category C (per Desoxyn label)
| legal            = Schedule II
| legal            = Schedule II
| mechanism        = Monoamine releasing agent TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport
| mechanism        = Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport
| intro            = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.
| intro            = '''Methamphetamine''' is a CNS stimulant of the amphetamine class. It is FDA-approved (as '''Desoxyn''') for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.
| indications      = <problem slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>
| indications      = <problem slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/>
Line 50: Line 50:
| pk_elimination    = Urinary elimination is pH-dependent.
| pk_elimination    = Urinary elimination is pH-dependent.
| pharmacodynamics  = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.
| pharmacodynamics  = Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.
| interactions      = * '''MAOIs''' contraindicated (per label)
| interactions      = * '''MAOIs''', contraindicated (per label)
* '''Acidifying agents''' increase urinary clearance
* '''Acidifying agents''', increase urinary clearance
* '''Alkalinizing agents''' decrease urinary clearance
* '''Alkalinizing agents''', decrease urinary clearance
<pharmaInteractions/>
<pharmaInteractions/>
| pregnancy_details = Category C per Desoxyn label.
| pregnancy_details = Category C per Desoxyn label.
Line 63: Line 63:




[[Category:Stimulants]]
[[Category:Psychostimulants]]
[[Category:Amphetamines]]
[[Category:Amphetamines]]
[[Category:Psychostimulants]]
[[Category:Psychostimulants]]
[[Category:Phenethylamines]]
[[Category:Phenethylamines]]

Latest revision as of 03:16, 19 May 2026

Psychostimulant, Amphetamine
Methamphetamine
Desoxyn
Methamphetamine is a CNS stimulant of the amphetamine class. It is FDA-approved (as Desoxyn) for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

ADHD in children, adolescents, and adults4.0n=1
Obesity (short-term) 1 don't know
+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

  • Attention and focus👤 no reports yet⚕️ no reports yet
  • Wakefulness👤 no reports yet⚕️ no reports yet
  • Motivation and drive👤 no reports yet⚕️ no reports yet
  • Mild euphoria👤 no reports yet⚕️ no reports yet
  • Decreased appetite/Anorexia👤 no reports yet⚕️ no reports yet
  • Dry mouth👤 no reports yet⚕️ no reports yet
  • Elevated heart rate / blood pressure👤 no reports yet⚕️ no reports yet
  • Insomnia👤 no reports yet⚕️ no reports yet
  • Irritability👤 no reports yet⚕️ no reports yet
  • Anxiety👤 no reports yet⚕️ no reports yet
  • Headache👤 no reports yet⚕️ no reports yet
  • Weight loss👤 no reports yet⚕️ no reports yet
  • Palpitations👤 no reports yet⚕️ no reports yet
  • Jaw clenching / bruxism👤 no reports yet⚕️ no reports yet
  • Stereotyped behaviors👤 no reports yet⚕️ no reports yet
  • Agitation👤 no reports yet⚕️ no reports yet
  • Psychosis👤 no reports yet⚕️ no reports yet
  • Mania👤 no reports yet⚕️ no reports yet
  • Dependence / misuse👤 no reports yet⚕️ no reports yet
  • Tolerance👤 no reports yet⚕️ no reports yet
  • Serious cardiac event👤 no reports yet⚕️ no reports yet
  • Seizure/Epileptic fit👤 no reports yet⚕️ no reports yet
  • Hyperthermia👤 no reports yet⚕️ no reports yet
  • Serotonin syndrome👤 no reports yet⚕️ no reports yet
  • Withdrawal/Discontinuation Syndrome👤 no reports yet⚕️ no reports yet

+ Add an effect

Pharmacokinetics

Metabolism

Hepatic metabolism includes N-demethylation to amphetamine (an active metabolite).

Elimination

Urinary elimination is pH-dependent.

Pharmacodynamics

Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.

Interactions

  • MAOIs, contraindicated (per label)
  • Acidifying agents, increase urinary clearance
  • Alkalinizing agents, decrease urinary clearance
No interactions reported yet.

Pregnancy and lactation

Category C per Desoxyn label.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

Mixed amphetamine salts, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Dexmethylphenidate, Modafinil

References

Structure of Methamphetamine
Summary
Classes
Psychostimulant, Amphetamine
Common uses
Inattention0, Hyperactivity0, Obesity0
Pharmacy
Starting dose
5 mg PO
Preparations
Desoxyn 5 mg tabs
US FDA Max
25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label)
Pharmacology
Routes
Oral (prescribed)
Pregnancy
Category C (per Desoxyn label)
Legal status
Schedule II
Purported mechanism
Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport